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ABSTRACT
It is thought that aging in rats and humans is associated with increases in iron
accumulation and these increases in iron may be associated with increased cellular
apoptosis.

Here we examine the relationship between cardiac iron levels and

cardiomyocyte apoptosis in aged F344BN rats which were treated with an oral iron
chelator (Deferasirox; 100mg/kg body. weight/day) for 6 months. Compared with 6month controls, the levels of cardiac iron, cardiac apoptosis, FLC and DMT-1 were
higher in 33-month hearts. Deferasirox treatment for six months decreased cardiac iron
and this was associated with decreases in the number of apoptotic cardiac myocytes.
Age-associated increases in cardiac apoptosis were coupled with alterations in the
amount of Bcl-2 and Bax. Deferasirox treatment increased Bcl-2 expression and
decreased Bad and activated caspase-12 expression. Taken together, these data
suggest deferasirox may be effective in diminishing age-associated iron accumulation
and cardiac apoptosis in the aging F344BN rat model.
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CHAPTER 1
Introduction
Improved medical care and prevention efforts have contributed to dramatic
increases in life expectancy in the United States [1]. By the year 2030, the number of
individuals 65 years and older will reach 70 million in the United States alone while
persons 85 years and older are expected to be the fastest growing segment of the
population [1]. Advanced age is a primary risk factor for cardiovascular disease (CVD).
In the United States, CVD alone accounts for over 40 percent of deaths in those aged
65 years and above and over 80 percent of all cardiovascular deaths occur in this same
age group [2]. Clearly, new interventions designed to diminish the incidence or severity
of CVD would serve to not only diminish morbidity and mortality, but, also the
burgeoning health care costs associated with treating the aged.
Aging is defined as a gradual decline of the ability of the organism to defend
against stress, damage and disease [3]. One of the most well known theories of aging is
Harman’s oxidative stress theory which postulates that the over production of free
radicals damage lipids, proteins, and DNA [3]. Reactive oxygen species (ROS) are a
family of free radicals including superoxide (·O2-), hydroxyl radical (OH·) and hydrogen
peroxide (H2O2) that are produced in the heart, and other tissues as a result of cellular
metabolism [4]. Oxidation of biomolecules due to increased ROS production can alter
the structure and function of lipids, proteins, and nucleic acids, leading to cellular
dysfunction and even cell death [4].
Although not well understood, it is likely that iron contributes to age-associated
increases in free radical generation. The majority of total body iron is incorporated into
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haem proteins that include haemoglobin, myoglobin and cytochromes [5]. Additionally,
the body also contains a pool of non-haem iron that it retains in reserve and for use as a
cofactor in iron-containing enzymes [5]. As a transition metal, iron possesses the ability
to fluctuate between multiple oxidation states which gives it the ability to produce
extremely reactive radical species. For example, in the presence of hydrogen peroxide
(H2O2), iron catalyses the formation of the highly reactive hydroxyl radical (·OH) via
Fenton chemistry [6]. Iron accumulation has been shown to occur during aging in a
variety of tissues, including the liver [7, 8], kidney [7, 8], brain [7, 8], heart [8]. Given the
ability of iron to participate in the formation of ROS it is likely that age-associated
increases in cardiac iron may contribute to the increased oxidative stress and cellular
dysfunction observed in the aging heart.
Cardiac complications of transfusional siderosis are the most important cause of
mortality in thalassemic patients as cardiomyocytes are quite vulnerable to the toxic
effects of excess iron [9]. To diminish the effects of excess iron accumulation in aging,
iron chelation therapy may be useful. Iron-chelating therapy with deferoxamine (DFO)
results in a significant improvement in the life expectancy of patients with transfusional
iron overload [10]. This increased longevity is largely attributed to the prevention of
heart disease in well-treated patients and, in a few, to the reversal of existing heart
disease by aggressive intravenous DFO therapy [10]. Unfortunately, compliance with
the rigorous requirements of daily subcutaneous DFO infusions is still a serious limiting
factor in treatment success.
The development of orally effective iron chelators such as Deferasirox (Exjade)
was motivated at least in part to improve compliance [11]. It is approved for the
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treatment of chronic iron overload due to blood transfusions in patients 2 years of age
and older [12]. The primary findings of Phase I and II studies of deferasirox use
demonstrated dose-related increases in iron excretion and the absence of significant
acute side effects other than gastrointestinal disturbances that were generally mild or a
diffuse rash that appeared to be more common at higher doses [12]. Characteristics of
deferasirox that make it attractive for oral dosing are a half-life of 8 - 16 hours which
allow a once daily administration [12].
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Purpose of the Study
The long term goal is to identify if the efficacy of iron chelation is efficacious in
reducing age-associated increases in cardiac iron. The purpose of this study is to
determine if deferasirox is capable of diminishing age-associated increases in cardiac
iron levels.
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Specific Aims and Hypothesis

It is estimated that by 2053, nearly 25% individuals in the United States will be
sixty-five years of age or older. Advancing age is associated with the development of
cardiovascular disease. Although not well understood, recent data has suggested that
age-related increases in cardiac ROS levels may be associated with cardiovascular
disease. It is thought that iron accumulation can lead to increased tissue ROS. The
working hypothesis of this study is that aging in F344BN animals would be associated
with increases in the cardiac iron content and that deferasirox treatment would be
efficacious in decreasing tissue iron levels. To test this hypothesis two specific aims are
proposed.
Specific Aim 1:

To determine if aging in F344BN rats associated with increases in
cardiac iron content.

Hypothesis 1:

Aging in F344BN rats will be associated with increases in cardiac
iron content.

Specific Aim 2:

To determine if iron chelation by deferasirox is effective in reducing
cardiac iron and cardiomyocyte apoptosis.

Hypothesis 2:

Iron chelation by deferasirox will be effective in reducing cardiac
iron and cardiomyocyte apoptosis.
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CHAPTER 2
REVIEW OF LITERATURE

This chapter will describe the literature regarding effects of aging on
cardiovascular structure and function, reactive oxygen species, apoptosis, regulation of
tissue iron, age-associated cardiac iron accumulation, iron chelation, and Deferasirox.

Effects of aging on cardiovascular structure and function
Cardiovascular diseases such as atherosclerosis and hypertension that lead to
heart failure and stroke are the leading cause of mortality in those 65 years and older
[2]. The clinical manifestations and prognosis of these diseases and resultant heart
failure worsen with increasing age [13].
Structural changes in the aging heart include cardiomyocyte loss, left ventricular
(LV) hypertrophy, changes of ventricle chamber diameter, and collagen deposition [1416]. Functionally speaking, aging in the heart is associated with lengthening of
contraction / relaxation times and thus a decrease in heart rate [17], decreases in
fractional shortening, decreased LV end-systolic pressure, and reduced cardiac output
[17, 18]. Cardiac structure and function are remarkably similar among mammalian
species, and the use of animal models has been extremely helpful in developing
treatment strategies for alleviating heart disease in humans [19]. Similar to that seen in
humans, aging in the Fischer 344 (F344) rat is characterized by myocyte loss and
reactive hypertrophy of the remaining cardiomyocytes [20]. The mechanisms of myocyte
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loss appear to be via cardiomyocyte apoptosis and/or necrosis. The causes of tissue
death are not well understood, but may be related to mitochondrial dysfunction [19].
Although F344 rat model are frequently used for aging studies, the Fischer 344/N
X Brown Norway (F344BN) hybrid exhibits significantly fewer pathological conditions,
resulting in an increased life expectancy [21]. Recent work has demonstrated that aging
in the F344BN like humans is associated with alterations in cardiac structure and
function [19]. Specifically, aging in these animals was characterized by increases in left
ventricular mass, left ventricular mass/body weight ratio, posterior wall thickness/body
weight ratio, anterior thickness/body weight ratio, and left ventricular chamber
diameter/body weight ratio. The mechanisms behind age-related changes in cardiac
structure and function remain to be determined.

Reactive oxygen species
Reactive oxygen species (ROS) such as superoxide (·O2-), hydroxyl radical (OH·)
and hydrogen peroxide (H2O2) are produced in the heart as a result of cellular
metabolism. Under normal physiological conditions, superoxide (·O2-) is converted to
the H2O2 by superoxide dismutase (SOD) and eventually the H2O2 is converted in to
H2O by catalase and glutathione peroxidase[22]. However, with aging, the production
of ROS in the heart may exceed the buffering capacity and oxidative damage may
result. Oxidation of biomolecules can alter the lipids, proteins, and nucleic acids
structure and function which if allowed to proceed unchecked can lead to cellular
dysfunction and even cell death.
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Although the exact mechanism of redox disruption is not clear, the free radical
theory points out increased amounts ·O2- and deceased amounts of nitric oxide
formation (NO) or its bioavailability with aging as strong candidates [23]. Whether the
disruption of redox balance is caused by overproduction of ROS, a deficiency in the
amount of antioxidants, or a combination of the two, is not clear.

Apoptosis
Apoptosis is a distinct form of cell death that displays characteristic alterations in
cell morphology and cell fate [24]. Chromatin condensation and margination that result
in a “half-moon” or “horseshoe” appearance of the nucleus are typical features of
apoptotic cell death [24]. In terms of tissue kinetics, apoptosis may be considered a
mechanism that counter balances the effect of cell proliferation. The deregulation of
apoptosis has been implicated as a pathogenetic mechanism in a variety of human
diseases [25]. Indeed, excessive apoptotic cell death may have been found to be
associated with organ atrophy and failure, as suggested for neurodegenerative
diseases and viral hepatitis [25]. Apoptotic cell death may also play a critical role in a
variety of cardiovascular diseases, including myocardial infarction, heart failure, and
atherosclerosis [25]. Conversely, the inefficient elimination of malignant, autoreactive,
infected, or redundant cells may lead to the development of neoplasia, autoimmunity,
viral persistence, and congenital malformations. The factors that regulate ageassociated apoptosis in the heart are not well understood.
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Iron
Iron is one of the most common elements in nature and, as a transition metal, is
essential for electron transport [11]. Iron is required for the functioning of proteins
involved in oxidative energy production, hemoglobin synthesis, oxygen transport,
mitochondrial respiration, and DNA synthesis [11]. Because of its poor solubility, living
organisms have been compelled to develop efficient mechanisms for iron transport and
storage[11]. The total amount of human body iron is approximately 3–4 g, two-thirds of
which is used for red blood cell (RBC) iron while the remainder is stored in ferritin /
hemosiderin [26]. In the circulation, iron is usually bound to transferrin (Tf), and most of
the Tf-bound iron is utilized for bone marrow erythropoiesis [26].
Iron homeostasis in tissues is regulated by a series of iron-regulatory proteins
that tightly control cellular iron uptake, storage, export and intracellular iron distribution.
Dysregulation of these iron-regulatory proteins can lead to intracellular iron overload
[27]. In thalassemic patients, ineffective erythropoiesis results in a drastic increase in
plasma iron turnover that is 10–15 times normal [28]. This wasteful production of
nonviable red blood cells (RBCs) stimulates iron absorption in addition to the iron
burden contributed by transfusions. Since the capacity of transferrin to carry iron is
limited, some of this catabolic iron emerges in the plasma in the form of non–transferrinbound iron (NTBI) [29, 30]. NTBI is readily available for Fenton type reactions, leading
to the conversion of reduced iron (Fe2+) to oxidized iron (Fe3+), thus generating
various free radicals [31, 32]. Under conditions of iron overload, iron in the circulation
typically exceeds the capacity of iron binding leading to an accumulation of NTBI [33,
34]. Excess uptake of NTBI into the cells combined with the lack of an effective iron
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excretory pathway often times leads to the formation of highly reactive oxygen radicals,
causing peroxidation of membrane lipids and oxidative damage to cellular proteins [31,
35, 36].
Iron-overload cardiomyopathy causes 71% of all deaths in patients with
thalassemia major [37]. Cardiac iron accumulation in iron overload patients has been
shown to directly correlate with heart diseases such as cardiac arrhythmias, heart
failure and mortality [38-40]. In situations of chronic iron elevation, excessive free
radical generation can lead to the depletion of antioxidants and increased cellular
damage due to the oxidation of lipids, proteins and nucleic acids [32].

Age-associated iron accumulation
Iron is a catalyst for the formation of reactive oxygen species in biological
systems. It is well accepted that iron accumulates with senescence in several organs
[8]. Excess iron can cause serious cellular and tissue damage through its ability to
formation of highly reactive hydroxyl radicals by electron transfer [41]. Such free
radicals can damage proteins, lipids and DNA, leading to destruction of organelles, cell
death and fibrosis. The clinical effects of excess tissue iron include heart disease,
hepatic dysfunction, and derangement of the endocrine system.
Although excess iron may be deposited in almost all tissues, most of it is found
in the reticuloendothelial (RE) cells in the spleen, hepatic Kupffer cells and bone
marrow, and in parenchymal tissues, such as the myocardium, liver, and endocrine
organs. In contrast to RE cells where iron accumulation is relatively harmless,
parenchymal siderosis may result in significant organ damage. Indeed, heart cells are
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among the most vulnerable to the toxic effects of excess iron, and cardiac complications
of transfusional siderosis are the most important cause of mortality in thalassemic
patients [9].

Fe (III)

Fe (II)

ROS

Apoptosis

Iron Chelation
Chelation therapy is the administration of chelating agents to remove heavy
metals like iron, lead, arsenic, mercury from the body. Iron chelation therapy forms an
important part of treatment for patients receiving therapy for chronic anemias, bthalassemia, sickle cell disease (SCD), and the myelodysplastic syndromes (MDS) [42]
To diminish these effects of excess iron accumulation in aging, iron chelation
therapy has been used. Iron-chelating therapy with deferoxamine (DFO) results in a
significant improvement in the life expectancy of patients with transfusional iron
overload. This increase in time to death is largely attributed to the prevention of heart
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disease in well-treated patients and, in a few, to the reversal of existing heart disease by
aggressive intravenous DFO therapy [10]. In a recent report on thalassemic patients
treated with DFO, survival at 40 years was 83%, and in compliant patients born after
1975, survival at 25 years was 100% [43]. This improvement in survival was reflected in
an inverse, mirror like decrease in cardiac mortality supporting the assumption that
prevention of cardiac mortality is the most important beneficial effect of DFO therapy
[44]. The strongest direct evidence supporting the beneficial effect of DFO on
hemosiderotic heart disease is the reversal of established myocardiopathy in some far
advanced cases [44]. Previously, the course of established myocardial disease in
transfusional hemosiderosis was considered fatal [44] however more recent data has
suggest that patients may still be salvaged by intensified chelation treatment [44].
Prevention of cardiac mortality is the most important beneficial effect of iron chelation
therapy. Unfortunately, compliance is poor given the requirement of daily subcutaneous
deferoxamine (DFO) infusions. The development of orally effective iron chelators such
as deferasirox (ICL670) has been driven as a means to improve compliance [11].

Deferasirox
Deferasirox (ICL670, Exjade®) is the first orally active iron chelator available for
routine use in the United States. It is approved for the treatment of chronic iron overload
due to blood transfusions in patients 2 years of age and older [12]. As a tridentate
chelator, two molecules of deferasirox bind one molecule of iron. The half-life of 8-16
hours allows once daily administration [12]. Iron excretion is mainly in the feces [12].
The primary findings in Phase I and II studies of deferasirox were dose-related
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increases in iron excretion and the absence of significant acute side effects other than
gastrointestinal disturbances that were generally mild and a diffuse rash that appeared
to be more common at higher doses. Evaluation of patient satisfaction with therapy has
demonstrated superiority of deferasirox over DFO which is hoped to translate into
improved compliance [42]. Whether deferasirox is capable of diminishing cardiac iron
levels is not well understood.
Binding of deferasirox with iron

(journals.prous.com/.../images/struc01.gif)
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Summary
Cardiovascular disease is leading cause of mortality in aged people. Aging is
associated with changes in cardiovascular structure and impairments in function.
Reactive oxygen species (ROS) increase with age and it is thought that increased
cardiac ROS can lead to the oxidation of biomolecules and increased cardiac apoptosis.
Iron has been found to accumulate in the heart with age and it has been postulated that
this increase in cardiac iron may lead to increased ROS. The effects of iron chelation on
age-associated increases in cardiac iron levels are unknown. Exjade is a new class of
iron chelators that can be taken orally. To our knowledge, it is not known if deferasirox
is capable of attenuating age-associated increases in cardiac iron.
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CHAPTER 3
Deferasirox decreases age-associated iron accumulation in the aging F344BN rat
heart

Note: Chapter 3 has been formatted for publication purposes.
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Abstract
It is thought that aging in rats and humans is associated with increases in iron
accumulation and that these increases in tissue iron may be associated with increased
cellular apoptosis. Here we examine the relationship between cardiac iron levels and
cardiomyocyte apoptosis in aged F344BN rats that had been treated with an oral iron
chelator (Deferasirox; 100 mg / kg body weight / day) daily for 6 months. Compared
with tissues obtained from 6-month control animals, the amount of cardiac iron (+72%),
ferritin light chain (+59%), divalent metal transporter-1 (+56%) and the level of cardiac
apoptosis (+89%) were higher in 33-month aged hearts (P<0.05). Deferasirox treatment
for six months decreased cardiac iron levels by 37% (P<0.05) and this was associated
with decreases in the number of apoptotic cardiac myocytes. Age-associated increases
in cardiac apoptosis were coupled with alterations in the amount of Bcl-2 and Bax.
Deferasirox treatment increased Bcl-2 expression 17% (P<0.05) and decreased Bad, a
proapoptotic protein and activated caspase-12 expression by 35% and 48%,
respectively (P< 0.05). Taken together, these data suggest deferasirox may be effective
in diminishing age-associated iron accumulation and cardiac apoptosis in the aging
F344BN rat model.

Wc =189
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Introduction
Advancing age is associated with an increased risk of cardiovascular diseases
[45]. Although not well understood, it is thought that the profound impact of age on the
risk of the occurrence, severity and prognosis of cardiovascular disease is due, in part,
to age-associated changes in cardiovascular structure and/or function [46]. Although
there is no clear consensus on the mechanism(s) that may be responsible for these
age-related alterations, increases in reactive oxygen species (ROS) and oxidative
stress have been posited as being involved [47]. The “free radical theory of aging”
proposes that aging allows for gradual damage to biomolecules via free radical
reactions [48]. The basis for these changes is still not fully understood, but it has been
reported that iron causes oxidative stress in the body while other studies have
demonstrated that aging in animals (rats) and humans is associated with increases in
iron accumulation [7, 49-51].
Cardiomyopathy from excess cardiac iron is the major cause of death in
thalassemia patients as iron accumulation in the heart has been linked to cardiac
hypertrophy, dilatation, and cardiac myocyte death [48, 52]. The survival of patients
with beta thalassemia and sickle cell anemia is determined by the magnitude of cardiac
iron-loading [52]. Iron chelation has been found to exert a beneficial cardiovascular
effect in most situations of iron overload, whether genetically determined (such as in
hemochromatosis) or caused by excessive transfusions. In addition, iron chelation or
deprivation has also been shown to act as a potent anti-oxidant in a variety of animal
models of human diseases, preventing oxidative stress to tissues and organs [53, 54].
Despite this evidence, the possibilities of pharmacologically targeting iron to improve
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“successful aging” or to reduce age-associated alterations in cardiovascular structure or
function have remained essentially unexplored.
We and others have demonstrated that aging in the Fischer 344BN rat model is
characterized by changes in cardiovascular morphology and function along with
increases in cardiac ROS [19, 55-57]. Whether these changes in the cardiovascular
system were associated with age-associated iron accumulation or if iron chelation may
be beneficial in diminishing these age-associated changes has not been investigated.
The purpose of this study was to examine if iron chelation was capable of reducing iron
in aging F344BN rats and to determine if changes in tissue iron levels, if present, were
associated with alterations in cardiac apoptosis and the expression of key regulators of
intracellular iron. We hypothesized that aging in F344BN animals would be associated
with increases in the cardiac iron content, cardiomyocyte apoptosis, and corresponding
changes is key intracellular iron regulators and that iron chelation would be effective in
reducing the magnitude of these variables. To test this hypothesis, we examined the
relationship between cardiac iron levels, cardiomyocyte apoptosis, and key intracellular
iron regulators in aged (33 month) control and treated F344BN rats that had been daily
treated with an oral iron chelator (Exjade; 100 mg / kg body weight / day) daily for 6
months. Taken together, our findings suggest that aging in the F344BN heart is
associated with increases in cardiac iron and cardiac apoptosis and that deferasirox is
effective in diminishing age-associated increases in each of these variables.
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Materials and Methods

Animals
Male Fischer F344BN rats (National Institute on Aging, Bethesda, MD), aged 6
and 27 months, and were housed in an AAALAC approved vivarium. Housing conditions
consisted of a 12:12 h light / dark cycle and temperature was maintained at 22 ± 2°C.
Water and food (LabDiet 5001, PMI Nutrition International, LLC, Brentwood, MO) were
provided ad libitum. Animals were allowed to acclimate to the housing facilities for at
least two weeks before experimentation began. During this time the animals were
carefully observed and weighed weekly. None of the animals exhibited signs of failure to
thrive, such as precipitous weight loss, disinterest in the environment, or unexpected
gait alterations. Animal care and procedures were conducted in accordance with the
Animal Use Review Board of Marshall University using the criteria outlined by the
American Association of Laboratory Animal Care (AALAC) as proclaimed in the Animal
Welfare Act (PL89-544, PL91-979, and PL94-279).

Materials
Antibodies against glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
(#2118), Bcl-2 (#2870), Bad (#9292), Bax (#2772), Caspase-12 (#2202), biotinylated
protein ladder, mouse and rabbit IgG antibodies were purchased from Cell Signaling
Technology (Beverly, MA). Ferritin light chain (FERL14-A), and divalent metal ion
transporter (DMT1) (NRAMP21-A) were procured from Alpha Diagnostic International
(San Antonio, TX). Transferrin receptor 1 (TfR1) was from AbD Serotec (Raleigh, NC).
Precast 10% SDS-PAGE gels were purchased from Cambrex Biosciences (Baltimore,
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MD), and enhanced chemiluminescence (ECL) western blot detection reagent was
acquired from Amersham Biosciences (Piscataway, NJ). Restore western blot stripping
buffer was obtained from Pierce (Rockford, IL) and 3T3 cell lysates were from Santa
Cruz Biotechnology (Santa Cruz, CA). All other chemicals were purchased from Sigma
(St. Louis, MO).

Iron chelation
To avoid the stress of chronic, repeated gavage feeding, deferasirox was
homogenously mixed in plain peanut butter for oral feeding via a 1-mL syringe (n=6 ea
group). Deferasirox was provided by Novartis Pharma, AG (Basel, Switzerland) and was
given at a single daily dosage of 100 mg/kg for six months as outlined previously [58].

Laboratory evaluation of iron-induced cardiac, liver, and renal damage
Appropriate whole blood and serum samples were obtained from rats at
necropsy and evaluated for cardiac toxicity (Alanine aminotransferase (ALT)), liver
toxicity (Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Alkaline
phosphatase (ALP), bilirubin), renal toxicity (Blood urea nitrogen (BUN), creatinine)
albumin (ALB),Calcium (Ca+2), Creatinine (CRE), Amylase (AMY), Globulin (GLOB),
Potassium

(K+), Sodium (Na+), Phosphorous (PHOS), Total bilirubin (TBIL), Total

protein (TP) utilizing a VetScan® Classic (Abaxis, Union City, CA, USA) with a
Comprehensive Diagnostic Profile Disk.
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Heart collection
Rats were anesthetized with a ketamine-xylazine (4:1) cocktail (50 mg/kg i.p.)
and supplemented as necessary for reflexive response. After midline laparotomy, the
heart was removed and placed in Krebs-Ringer bicarbonate buffer (KRB) containing:
118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 24.2 mM
NaHCO3, and 10 mM α-D-glucose (pH 7.4) equilibrated with 5% CO2/ 95% O2 and
maintained at 37°C. Isolated hearts were quickly massaged to remove any blood from
the ventricles, cleaned of connective tissue, weighed, and immediately snap frozen in
liquid nitrogen.

Determination of organ metal levels
Portions of the hearts, were removed, weighed, and sent for quantitative iron
determination (University of Tampa, Tampa, Fl) by inductively coupled plasma-atomic
emission spectroscopy (ICP-AES), (n=6) [59]. Briefly, digestions were performed using
commercially available trace metal grade HNO3 (Thermo Fisher Scientific). Dilutions
were made with 2% (vol.) HNO3 (trace metal grade) prepared with deionized water. All
digestion tubes, volumetric pipettes, and volumetric glassware were soaked for 24
hours in 2% (vol.) HNO3 (trace metal grade), rinsed four times with deionized water, and
air dried prior to use. Approximately 300 mg (wet weight) of sample was weighed into a
glass digestion tube and 6.0 ml of concentrated trace metal grade HNO 3 added. A 1000
mg/L Yttrium solution in 2% HNO3 (PerkinElmer), used as an internal standard (final
concentration 1.67 mg/L), was added to each tube. Samples were heated at 37 oC for 1
hour and then at 110oC for 2 hours. After digestion, 5.0 ml of the clear solution was
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transferred to a 50 ml volumetric flask and brought to volume with 2% (vol) HNO 3 (trace
metal grade).

Solutions were filtered through a 0.22 μm syringe driven filter unit

(Millipore) and analyzed by Inductively Coupled Plasma-Atomic Emission Spectroscopy
(ICP-AES). A 1.67 mg/L iron solution was used as a control for the digestion procedure.
Analyses were performed on a Perkin Elmer ICP-AES (Optima 2100 DV) using a 0 to 1
mg/L, 0 to 10 mg/L, or 0 to 100 mg/L (for iron only) standard curve, depending upon the
metal concentration. Calibration and control solutions for the 0 to 1 mg/L and 0 to 10
mg/L standard curves were prepared from a multi-element standard (ICP Multi-element
Solution 2, Spex Chemicals, 10 mg/L). Calibration and control solutions for the 0 to 100
mg/L standard curve were prepared from a 1000 mg/L iron standard solution
(PerkinElmer, Waltham, MA). All calibrators and controls contained an internal Yttrium
standard. The measurements for iron (238.204 nm), copper (327.393 nm), zinc
(206.200 nm), magnesium (280.271 nm), and manganese (257.610 nm) were
conducted in the axial mode, while calcium (393.366 nm) was measured in the radial
mode. Sample concentrations were determined from standard curves generated by
linear regression analysis. The minimal detectable concentration for each metal was
determined using the mean plus the three-fold standard deviation obtained from 10
blank digestions.

TUNEL staining
DNA fragmentation was determined by TdT-mediated dUTP nick end labeling
(TUNEL) according to the manufacturer’s recommendations.

TUNEL staining was

performed on tissue sections (8 μm) obtained from 6- (n = 6), 33 control- (n = 6), and 33
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treated- (n = 6) month hearts, which were fixed with 4% paraformaldehyde, washed with
PBS (pH 7.4), and then permeabilized with 0.1% sodium citrate and 0.1% Triton X.
Cross-sections from each heart were treated with DNase I to induce DNA fragmentation
as a positive control. Three randomly selected regions from each cross section were
visualized by epifluorescence using an Olympus fluorescence microscope (Melville, NY)
fitted with a 20X objective.

Images were recorded digitally using a CCD camera

(Olympus, Melville, NY), and the samples were analyzed by counting positively stained
nuclei.

Immunoblot analysis
Hearts were pulverized in liquid nitrogen using a mortar and pestle until a fine
powder was obtained. After washing with ice cold PBS, samples were lysed on ice for
15 min in T-PER (2 ml/1g tissue weight) and centrifuged for 10 min at 12000 x g. The
supernatant was collected and the protein concentrations of homogenates were
determined in triplicate via the Bradford method (Pierce) using bovine serum albumin as
a standard. Samples were solubilized at a concentration of 3mg/ml in SDS-loading
buffer and boiled for 5 minutes. forty µg of protein from each sample was separated on
10% SDS-PAGE gels and then transferred onto Hybond nitrocellulose membranes
using standard conditions [60].
To verify transfer of proteins and equal loading of lanes the membranes were
stained with Ponceau S. For immunodetection, membranes were blocked in 5% milk
Tris buffered saline with 0.5% tween-20 (TBST) for 1 hr at room temperature and then
incubated with the appropriate primary antibody overnight. After washing in TBST, the
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membranes were exposed to horseradish peroxidase-(HRP)-labeled IgG secondary
antibody for 1 hr and protein bands were visualized with ECL (Amersham Biosciences).
Exposure time was adjusted to keep the integrated optical densities (IODs) within a
linear and nonsaturated range. Band signal intensity was quantified by densitometry
using a flatbed scanner (Epson Perfection 3200 PHOTO) and Imaging software
(AlphaEaseFC).

Equal protein loading between lanes and gels was determined by

normalizing to the amount of Ponceau S stained protein transferred to the membranes
or by GAPDH intensity. Molecular weight markers (Cell Signaling) were used as
molecular mass standards and NIH 3T3 cell lysates were included as positive controls.
At least three SDS-PAGE gels were run for each experimental set to evaluate changes
in dependent variable tissue content and basal phosphorylation where applicable.
Immunoblots were stripped with Restore western blot stripping buffer as described by
the manufacturer to obtain direct comparisons between expression and phosphorylation
levels of different signaling molecules. After verifying the absence of residual HRP
activity by reacting with the membrane with the ECL reagent, membranes were washed
and reprobed.

Data analysis
Results are presented as means ± SEM. Data were analyzed by using the
SigmaStat v.3.5 statistical program. Oneway analysis of variance (ANOVA) was
performed for overall comparisons while the Student-Newman-Keuls post hoc test used
to determine differences between groups.

Regression analysis of the dependent
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variables was performed across age groups using values from six individual hearts from
each group. Values of P < 0.05 were considered to be statistically significant.
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Results
Total body and heart weights were obtained and compared (Table 1).

All

animals tolerated the chelation without any apparent ill effects. The body weights of the
treatment and age matched control were similar to 6-month controls. Compared to 6month animals, aging increased the heart to body weight ratio by 46% (P < 0.05), (Table
1). Deferasirox treatment did not alter the heart to body weight ratio.

Deferasirox decreases age-associated increases in cardiac iron
Compared to tissues obtained from 6-month control animals, the iron content of
the aged heart was 72% higher (P<0.05) (Fig.1). Deferasirox treatment for six months
decreased cardiac iron levels by 37% (P<0.05). Neither aging nor deferasirox treatment
altered cardiac copper, zinc or magnesium levels (Table 1). Tissue levels of calcium
were 53% higher in the 33-month control hearts (P<0.05) compared to 6-month control
hearts.

Aging increases the expression of iron regulatory proteins
Compared to 6-month control animals, the amount of ferritin light chain was 57%
and 83% higher in 33-month control and 33-month treated animals, respectively
(P<0.05) (Table 2). Similarly, DMT-1 levels were 57% and 78% higher in 33-month
control and 33-month treated animals, respectively (P<0.05) (Fig. 2). IRP-1 and TfR-1
levels were unchanged with both aging and treatment.
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Age-associated changes in indices of liver and kidney function
Compared to 6-month control animals, ALP, BUN and PHOS levels in venous
blood were 7%, 24%, and 35% lower, respectively (P<0.05) (Table 3). Globulin and Na+
levels were 33% and 5% higher in aged animals compared to that observed in 6-month
control animals (P<0.05) and unaltered by deferasirox treatment (Table 3). Deferasirox
treatment for 6-months decreased the ALP levels by 26% compared to age matched
control animals (P<0.05) (Table 3). Changes in the other blood parameters were not
significantly different with age or treatment.

Deferasirox treatment decreases indices of age-associated cardiomyocyte
apoptosis
Compared to 6-month animals, the number of TUNEL positive cells was
approximately 15.7 times

higher in 33-month control animals and with deferasirox

treatment it was demonstrated that the number of TUNEL positive cells was decreased
by 67.1% compared to age matched controls (P< 0.05) (Fig. 3).

The ratio of Bax and

Bcl-2 expression is thought to be key regulator of apoptosis [61]. Aging was associated
with higher levels of Bax (P< 0.05) while Bcl-2 levels were unchanged (Fig. 4, Table 2).
Similarly, the expression of Bad was 28% higher (P< 0.05) in 33-month old animals (Fig.
5).

Compared to age-matched controls, deferasirox decreased Bad and activated

caspase-12 expression by 49% and 18%, respectively (P< 0.05) (Figs. 5, 6).
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Discussion
Recent data has suggested age-related increases in iron may lead to increased
levels of redox-active iron and iron-mediated oxidative stress [62]. In the aging heart,
increases in oxidative stress have been posited to play a role in dysrhythmia, cardiac
injury, and cardiomyocyte death [63]. In comparison to other rat strains, the F344BN
appears to exhibit diminished age-related pathophysiology leading some to hypothesize
that this model may be more appropriate than others for investigation of the effects of
aging on physiological function [21, 64, 65]. We and others have recently demonstrated
that aging in the F344BN is associated with increases in heart mass, left ventricular
hypertrophy, increased incidence of cardiac arrhythmias, decreased ventricular
compliance and impairment in systolic and diastolic function [19, 57] as well as
increased expression of oxidative-nitrosative stress markers in the myocardium [55]. As
in humans, the induction mechanisms that underlie these degenerative changes are not
fully understood.

Here we examine if aging in the F344BN rat is associated with

increased tissue iron levels, if iron chelation can influence tissue iron in the aging
F344BN, and whether a relationship exists between cardiac iron levels and
cardiomyocyte death.
It is difficult to gauge iron status, particularly iron stores, based on traditional
laboratory tests which are often confounded by the presence of infection, inflammation
or disease in older adults [66, 67]. Several investigations have, therefore, focused on
examination of tissue iron stores with aging in various animal models. Consistent with
previous data obtained in the Sprague Dawley rat and humans [68, 69], here we
demonstrate that aging in the F344BN rat was associated with increased levels of
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cardiac and liver iron (Fig. 1). Iron is essential for critical life functions, including oxygen
transport, energy metabolism and cell proliferation. Given its biological importance, as
well as its toxicity, iron levels are typically precisely regulated under normal physiology
conditions via several intricate feedback mechanisms involving transporters, ironbinding proteins and receptors [51, 70]. Why aging might be associated with increased
cardiac iron levels has not been fully elucidated.
One major finding of the present study is that deferasirox appears to be
efficacious for the removal of cardiac iron in the aged rat (Fig. 1). In addition, these
data also suggest that deferasirox is quite specific as we failed to find any impact of
chronic deferasirox treatment on tissue calcium, copper, zinc or magnesium levels
(Table 2). To our knowledge these findings have not been demonstrated before in this
animal model. Consistent with previous data collected in aging Sprague Dawley rats
[71], we did not find any difference in tissue iron levels in aging kidney (data not shown).
Why some tissues appear to accumulate iron with aging while others do not is not well
understood but is likely related to differences in iron transport mechanisms between
different cell and tissue types [70].
To examine the possibility that the increased cardiac iron we observed is
associated with alterations in the expression of iron regulatory proteins we examined
the effects of aging on cardiac ferritin, divalent metal transporter-1 (DMT-1), transferrin
receptor-1 (TfR-1) and iron regulatory protein-1 (IRP-1) levels. Ferritin is a 24-subunit
protein comprised of heavy and light chains that has been shown to function as the
main intracellular storage protein for iron [72]. Conversely, DMT-1 and TfR-1 are iron
transport proteins that are thought to be involved in regulating the uptake of non-haem
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iron from the circulation [73] while IRP-1 has been demonstrated to regulate the
expression of critical iron regulation proteins at the post-translational level [74]. Similar
to recent work examining the regulation of iron regulatory proteins in the skeletal
muscles of aged F344 rats [68], we found that aging was associated with a significant
increase in the amount of cardiac ferritin light chains (Fig. 2).

Consistent with our

findings of age-associated cardiac iron accumulation, we also found that the aged
F344BN hearts also exhibited increased levels of DMT-1. Whether these increases in
the amount of DMT-1 and ferritin are fully responsible for the age-associated increases
in cardiac iron we observe or whether these factors act in concert with other
mechanisms is currently unknown. Although unlikely to play a major role, some have
proposed that oxidant stress itself may be involved in the accumulation of iron levels as
superoxide radicals have been observed to liberate iron from ferritin [75]. It is currently
unclear if this process is occurring in the aging F344BN heart and what degree this
process, if present, may play in increasing tissue iron levels will require further
investigation.
Given that the length of deferasirox treatment (6 months) used in this study is
likely quite similar to several decades of human life we examined several different blood
parameters in an attempt to ascertain if chronic deferasirox administration adversely
affected animal health [76]. With the exception of alkaline phosphatase (ALP) levels,
which were decreased but within the normal range, no significant differences in any of
the parameters measured were observed in treated compared to age-matched control
animals (Table 2).

Taken together, these data suggest that long term deferasirox

treatment is not associated with poor animal health in the F344BN aging rat model.
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Recent evidence has suggested that apoptosis may play a considerable role in
mediating age-associated cardiac dysfunction in both rats and humans [77]. Indeed,
increased myocyte apoptosis is directly related to dysfunction and pathology in the heart
exhibited with aging, cardiovascular disease, cardiomyopathy and heart failure.
Intriguing evidence also indicates that apoptotic signaling and caspase activation
increases protein degradation and impairs contractile function, independent of cell loss
[78]. Here we observed an increase in the number of cells exhibiting morphological
changes consistent programmed cell death or apoptosis. Specifically, with aging we
demonstrate an increase in the number of nuclei staining positive for DNA strand
breakage as determined by the TUNEL assay (Fig. 2). This finding is in agreement with
the recent findings of Phaneuf and Leeuwenburgh who demonstrated an ageassociated increase in the number of apoptotic nuclei in the aging rat heart [79]. The
degree to which apoptosis contributes to myocyte loss and cardiac dysfunction in the
aging F344BN rat is not well understood. Nonetheless, the findings of the present study
are consistent with previous reports by our laboratory and others demonstrating that
cardiac function in the aging F344BN are impaired with aging [19, 57, 80]. In addition
these data also suggest that age related increases in cardiac iron may play a role in
cardiac apoptosis.

Importantly, we also demonstrate that deferasirox treatment is

associated with a decrease in the number of cardiomyocytes exhibiting a TUNEL
positive signal.

Whether the decreases in TUNEL positive cells we observe with

deferasirox treatment are associated with improvements in cardiac performance or are
directly linked to deferasirox induced changes in tissue iron levels is not known. Future
research aimed at investigating these research questions will no doubt be useful in
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addressing the potential for deferasirox for treating age-related cardiovascular
dysfunction.
The mechanism(s) regulating cardiac apoptosis are not fully understood.
Apoptotic signaling induces apoptosis primarily through three types of complex
pathways. They include 1) cytokine/Fas receptor-driven pathway, 2) mitochondrialdriven pathway, and 3) endoplasmic reticulum/Ca2+-driven pathway [81]. Among them,
the mitochondrial-mediated pathway, including the Bcl-2 family is the best characterized
and believed to be critical in regulating apoptosis with aging [77]. Indeed, progressive
impairment of mitochondrial function is a hallmark of aging and has been linked with
apoptosis.

Although this pathway includes multiple proteins, the regulation and

interaction of the anti-apoptotic Bcl-2 and the pro-apoptotic Bax appear to play key
roles. Current research suggests that Bcl-2 forms a heterodimer with Bax that prevents
Bax homodimerization, its insertion into the mitochondrial membrane, and the release of
cytochrome-c [82]. It is thought that the ratio of Bax to Bcl-2 plays an important role in
regulating the release of cytochrome-c from the mitochondria into the cytosol with the
release of cytochrome-c and cell death favored as the balance shifts toward Bax [83].
Consistent with the TUNEL findings, we observed a large increase in the amount of Bax
in the aging F344BN heart (Fig. 4). To further confirm the possibility that that Bcl-2 /
Bax might be involved in the cardiac apoptosis we also examined the effects of aging on
Bad expression. Bad is a pro-apoptotic member of the Bcl-2 family that can displace
Bax binding from Bcl-2 and Bcl-XL, resulting in cell death [84]. Similar to Bax, we
observed that Bad levels increased with aging (Fig. 5).

Importantly, we also

demonstrate that deferasirox treatment is associated with a significant increase in the
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anti-apoptotic Bcl-2 and a decrease in pro-apoptotic Bad. Taken together, these data
suggest that the mitochondrial-mediated processes may play a role in age-associated
cardiomyocyte death and that deferasirox may decrease age-associated cardiomyocyte
apoptosis, possibly be altering the expression of Bcl-2 and Bad.
In an effort to examine other mechanisms of apoptosis we also examined the
regulation of caspase-12 (Fig. 6).

Caspase-12 is one of the key effectors of the

endoplasmic reticulum/Ca2+-driven pathway that is thought to be activated in response
to calcium dyshomeostasis or endoplasmic reticulum (ER) stress [85]. Here, we failed
to observe any age-associated changes in the amount of cleaved (activated) caspase12 suggesting perhaps that ER stress does not play a major role in regulating cardiac
apoptosis in the aging F344BN heart (Fig. 6). Nonetheless, it is of interest to note that
we found that deferasirox treatment appeared to decrease the amount of caspase-12
activation. Whether this treatment associated change in caspase-12 is also associated
with the decrease in the number of TUNEL positive cells we observed with deferasirox
treatment is unknown.
Taken together, the data of the present study suggest that deferasirox treatment
can effectively reduce age-associated increases in cardiac iron and cardiomyocyte
apoptosis. Future studies examining other animal models and other indices of ageassociated dysfunction will no doubt be useful in determining the usefulness of
deferasirox as an intervention.
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CHAPTER 4
Conclusions

1. Aging increases cardiac iron content in F344BN rats.
2. Increased cardiac iron content with age alters the expression of proteins
associated with apoptotic signaling.
3. Increased cardiac iron content with age alters the expression of proteins thought
to be involved in regulating tissue iron levels.
4. Iron chelation by deferasirox is effective in reducing cardiac iron content in
F344BN rats.
5. Iron chelation by deferasirox is effective in reducing cardiomyocyte apoptosis.
6. Iron chelation by deferasirox is effective in reducing in corresponding changes in
key intracellular iron regulators.
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Future Directions

In this present study we examined the effects of aging on cardiac iron
accumulation and whether or not deferasirox was efficacious in reducing cardiac iron
content. To continue this study, future investigations could examine the effects of aging
and deferasirox treatment on iron accumulation in other vital organs such as the liver,
kidney and skeletal muscles.
Other work could explore the possibility of including other chelators with
deferasirox to determine if combination therapy would lead to synergistic or additive
effects.
Finally, in the present study we used only the F344BN rat model. Whether
deferasirox would have similar effects in other aging models or humans is currently
unclear. Future studies addressing this possibility would no doubt be useful in furthering
our understanding of the effects of age and chelation on tissue iron levels.
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Appendix A
Table Legends

Table 1. Effect of aging on heart weight and cardiac metal content and indices of
liver and kidney function in 6-, 33-month control and 33-month treated F344BN
rats.

Table 2. Tissue concentration of protein in hearts excised from young adult (6
month), aged controls (33-month), and aged animals that had been treated with
deferasirox for 6-months (33-month treated) F344BN rats. Data was obtained from
immunoblotting analysis. Data are presented as percentages of the young adult value ±
SE. The results reflect the analysis of combined protein comparisons of four individual
hearts from each age group. An asterisk (*) designates significant differences from 6month age group (P < 0.05).

Table 3. Effect of aging on indices of liver and kidney function in 6-, 33-month
control and 33-month treated rats.
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Table 1
6month
control

33month
control

33month
treated

Physical
characteristics
Body wt (g)

440 ± 24

512 ± 34*

472 ± 46

Heart/body wt (%)

0.25 ± 0.01

0.37 ± 0.01*

0.41 ± 0.02*

Calcium

0.045 ± 0.006

0.096 ± 0.015*

0.073 ± 0.017

Copper

2.872 ± 0.420

3.45 ± 0.558

3.616 ± 0.120

17.501 ± 4.558

17.145 ± 1.842

16.987 ± 0.273

0.196 ± 0.011

0.231 ± 0.030

0.192 ± 0.022

Trace metals

Zinc
Magnesium

An asterisk (*) indicates significant difference (P<0.05) from the 6-month control group.
(n=6).
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Table 2
6month
control

33month
control

33month
treated

Ferritin Heavy Chain

100 ± 2

94 ± 2*

90 ± 1*

Ferritin Light Chain

100 ± 6

159 ± 16*

183 ± 13*

Divalent Metal Transporter-1

100 ±7

156 ± 14*

178 ± 16*

Iron Regulatory Protein-1

100 ± 5

113 ± 4

103 ± 8

Transferrin Receptor-1

100 ± 2

119 ± 5

111 ± 7

Iron regulatory factors

An asterisk (*) or cross (†) indicates significant difference (P<0.05) from 6-month control
and sham chelation groups, respectively (n=6)
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Table 3
6month
control

33month
control

33month
treated

3.2 ± 0.1

4 ± 0.2

3 ± 0.4

ALP(u/l)

182 ± 13.7

169 ± 7.4 *

124 ± 9.9 *†

ALT(u/l)

43 ± 4.4

90 ± 19.0

47 ± 7.2

AMY(u/l)

750 ± 79.1

931 ± 134.1

715 ± 70.8

BUN(mg/dl)

23 ± 1.1

17 ± 1.0 *

13 ± 1.2 *

Ca+2(mg/dl)

11 ± 0.2

11 ± 0.2

11 ± 0.4

CRE(mg/dl)

0.5 ± 0.1

0.3 ± 0.1

1.5 ± 0.9

GLOB(g/dl)

2 ± 0.1

3 ± 0.2 *

3 ± 0.1 *

K+(mmol/l)

8 ± 0.3

6 ± 0.1

6 ± 0.4 *

Na+(mmol/l)

142 ± 2.4

149 ± 2.6 *

150 ± 1.7 *

PHOS(mg/dl)

13 ± 1.2

8 ± 0.8 *

8 ± 0.2 *

0.3 ± 0.03

0.4 ± 0.01

0.4 ± 0.03

6 ± 0.2

7 ± 0.4

6 ± 0.4

Blood parameters
ALB(g/dl)

TBIL(mg/dl)
TP(g/dl)

An asterisk (*) or cross (†) indicates significant difference (P<0.05) from age matched
control and sham chelation groups, respectively (n=6)
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Figure Legends

Figure 1. Deferasirox treatment prevents age-associated increases in cardiac
iron. Tissue iron levels of rats in the experimental groups as determined by ICP-AES
measurements.

(*) indicates significant difference from 6-month control animals

(P<0.05), (†) indicates significant difference from 33-month control animals (P<0.05).

Figure 2. Aged hearts exhibit increases in the amount of ferritin light chain and
divalent metal transporter-1. Protein content as determined by Western blot analysis.

Figure 3. Deferasirox treatment attenuates age-associated increases in cardiac
apoptosis. Representative cross-sections showing nuclei exhibiting DNA strand
breakage as determined by the TUNEL staining in 6-month, 33-month control and 33month treated animals.

Figure 4. Bax / Bcl2 content is increased with age. Protein content was determined
by performing Western blot analysis. Data are presented as means ± SE. * significantly
different from 6-month values (P<0.05). † Significantly different from 33-month control
values (P<0.05).
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Figure 5. Bad protein levels are higher with age and decreased by deferasirox
treatment. Protein content was determined by performing Western blot analysis. Data
are presented as means ± SE. *Significantly different from 6-month values (P<0.05). †
Significantly different from 33-month control values (P<0.05).

Figure 6. Deferasirox treatment decreases the amount of activated caspase-12.
Protein content was determined by performing Western blot analysis.

Data are

presented as means ± SE. * Significantly different from 6-month values (P<0.05). †
Significantly different from 33-month control values (P<0.05).
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Figure 1. Deferasirox treatment prevents age-associated increases in cardiac iron
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Figure 2. Aged hearts exhibit increases in the amount of ferritin light chain and
divalent metal transporter-1
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Figure 3. Deferasirox treatment attenuates age-associated increases in cardiac
apoptosis
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Figure 4. Bax / Bcl2 content is increased with age
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Figure 5. Bad protein levels are higher in aged rats and decreased by deferasirox
treatment
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Figure 6. Deferasirox treatment decreases the amount of activated caspase-12
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films

%C
%C
%C
N
Mean
Strandard Deviation
Standard Error of the mean

6m CON
33.70
37.40
36.30
3
35.80
1.90
1.34

33m CON
34.70
32.20
33.70
3
33.53
1.26
0.89

33m TRT
31.70
30.40
30.00
3
30.70
0.89
0.63

Relative Expression Level
Standard error of the mean

6m CON
1.00
0.04

33m CON
0.94
0.02

33m TRT
0.86
0.02

% RE
SE

6m CON
33m CON 33m TRT
100
93.668529 85.75419
3.752801353 2.4853534 1.7555594
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One Way Analysis of Variance
Data source: Data 1 in Notebook 1
Normality Test:

Passed

Equal Variance Test:
Group Name
6 Cont
3
33m Cont 3
33 m Trt
3

N
0
0
0

Source of Variation DF
Between Groups
2
Residual
6
Total
8

(P = 0.786)

Passed

(P = 0.488)

Missing Mean Std Dev
35.800 1.900 1.097
33.533 1.258 0.726
30.700 0.889 0.513

SEM

SS
MS
F
P
39.176 19.588 9.821 0.013
11.967 1.994
51.142

The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.013).
Power of performed test with alpha = 0.050: 0.828

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means
6 Cont vs. 33 m Trt
5.100
6 Cont vs. 33m Cont
2.267
33m Cont vs. 33 m Trt 2.833

p
3
2
2

q
P
P<0.050
6.255 0.011 Yes
2.780 0.097
No
3.475 0.049 Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
Immunoblot films

%C
%C
%C
N
Mean
Strandard Deviation
Standard Error of the mean

Relative Expression Level
Standard error of the mean

% RE
SE

6m CON
33m CON 33 m TRT
26.30
37.10
36.60
20.30
41.70
38.00
24.40
45.50
30.10
3.00
3.00
3.00
23.66666667 41.433333
34.9
3.07
4.21
4.22
2.17
2.97
2.98
6m CON
1
0.09

33m CON 33m TRT
1.7507042 1.4746479
0.13
0.13

6m CON
33m CON 33m TRT
100
175.07042 147.46479
9.161969125 12.567611 12.59481
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One Way Analysis of Variance
Data source: Data 1 in Notebook 2
Normality Test:

Passed

Equal Variance Test:
Group Name
6m CON
3
33m CON 3
33 m TRT 3

N
0
0
0

(P = 0.391)

Passed

(P = 0.865)

Missing Mean Std Dev
23.667 3.066 1.770
41.433 4.206 2.429
34.900 4.215 2.434

SEM

Source of Variation DF
SS
MS
F
P
Between Groups
2
484.527 242.263 16.199 0.004
Residual
6
89.733 14.956
Total
8
574.260
The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.004).
Power of performed test with alpha = 0.050: 0.970

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method):
Comparisons for factor:
Comparison
Diff of Means
33m CON vs. 6m CON 17.767
33m CON vs. 33 m TRT 6.533
33 m TRT vs. 6m CON 11.233

p
3
2
2

q
P
P<0.050
7.957 0.003 Yes
2.926 0.084
No
5.031 0.012 Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films

%C
%C
%C

6m CON
42.9
29.90
29.70

33m CON
40.3
44.80
45.90

33m TRT
16.9
25.30
24.30

N
3
3
3
Mean
34.16666667 43.666667 22.166667
Strandard Deviation
7.56
2.97
4.59
Standard Error of the mean
5.35
2.10
3.24

Relative Expression Level
Standard error of the mean

% RE
SE

6m CON
33m CON 33m TRT
1
1.2780488 0.6487805
0.15654205 0.0614053 0.0949605
6 CON
33m CON 33m TRT
100 127.80488 64.878049
15.65420501 6.1405315 9.4960463
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One Way Analysis of Variance
Data source: Data 1 in Notebook 3
Normality Test:

Passed

Equal Variance Test:
Group Name
6 Cont
3
33m Cont 3
33 m Trt
3

N
0
0
0

(P = 0.501)

Passed

(P = 0.825)

Missing Mean Std Dev
34.167 7.564 4.367
43.667 2.967 1.713
22.167 4.588 2.649

SEM

Source of Variation DF
SS
MS
F
P
Between Groups
2
696.500 348.250 11.999 0.008
Residual
6
174.140 29.023
Total
8
870.640
The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.008).
Power of performed test with alpha = 0.050: 0.903

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means
33m Cont vs. 33 m Trt 21.500
33m Cont vs. 6 Cont
9.500
6 Cont vs. 33 m Trt
12.000

p
3
2
2

q
P
P<0.050
6.912 0.007 Yes
3.054 0.074
No
3.858 0.034 Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films

%C
%C
%C
N
Mean
Strandard Deviation
Standard Error of the mean

6m CON
40.00
26.10
23.30
3
32.35
16.40
11.59

33m CON
32.70
37.00
34.90
3
34.33
15.45
10.93

33m TRT
27.30
37.00
41.90
3
33.38
16.21
11.46

Relative Expression Level
Standard error of the mean

6m CON
1.00
0.36

33m CON
1.06
0.34

33m TRT
1.03
0.35

% RE
SE

6m CON
33m CON 33m TRT
100
106.1051 103.16847
35.83694698 33.779863 35.426509
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One Way Analysis of Variance
Data source: Data 1 in Notebook 4
Normality Test:

Passed

Equal Variance Test:
Group Name
6 Cont
3
33m Cont 3
33 m Trt
3

N
0
0
0

(P = 0.660)

Passed

(P = 0.493)

Missing Mean Std Dev
29.800 8.944 5.164
34.867 2.150 1.241
35.400 7.430 4.290

SEM

Source of Variation DF
SS
MS
F
P
Between Groups
2
57.316 28.658 0.615 0.572
Residual
6
279.647 46.608
Total
8
336.962
The differences in the mean values among the treatment groups are not great enough
to exclude the possibility that the difference is due to random sampling variability; there
is not a statistically significant difference (P = 0.572).
Power of performed test with alpha = 0.050: 0.050
The power of the performed test (0.050) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one
actually exists. Negative results should be interpreted cautiously.
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films

%C
%C
%C
N
Mean
Strandard Deviation
Standard Error of the mean

6m CON
41.80
36.80
34.50
3.00
38.725
17.61
12.45

33m CON
32.00
35.60
35.10
3.00
33.675
15.15
10.72

Relative Expression Level
Standard error of the mean

6m CON
1
0.32

33m CON 33m TRT
0.8695933 0.714009
0.28
0.23

% RE
SE

33m TRT
26.30
27.60
30.40
3.00
27.65
12.48
8.82

6m CON
33m CON 33m TRT
100
86.959329 71.400904
32.15169258 27.670401 22.784927
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One Way Analysis of Variance
Data source: Data 1 in Notebook 5
Normality Test:

Passed

Equal Variance Test:
Group Name
6 Cont
3
33m Cont 3
33 m Trt
3

N
0
0
0

(P = 0.786)

Passed

(P = 0.547)

Missing Mean Std Dev
37.700 3.732 2.155
34.233 1.950 1.126
28.100 2.095 1.210

SEM

Source of Variation DF
SS
MS
F
P
Between Groups
2
141.796 70.898 9.614 0.013
Residual
6
44.247 7.374
Total
8
186.042
The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.013).
Power of performed test with alpha = 0.050: 0.819

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method):
Comparisons for factor:
Comparison
Diff of Means
6 CON vs. 33 m TRT
9.600
6 CON vs. 33m CON
3.467
33m CON vs. 33 m TRT 6.133

p
3
2
2

q
P
P<0.050
6.123 0.012 Yes
2.211 0.169
No
3.912 0.033 Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films

%C
%C
%C
N
Mean
Strandard Deviation
Standard Error of the mean

6m CON
26.8
25.7
24.9
3
25.80
0.95
0.67

33m CON
34.5
36.2
33.5
3
34.73
1.37
0.97

33m TRT
38.7
38.1
41.6
3
39.47
1.87
1.32

Relative Expression Level
Standard error of the mean

6 m CON
1.00
0.03

33m CON
1.3463
0.04

33 m TRT
1.53
0.05

% RE
SE

6m CON
100.00
2.61

33m CON
134.63
3.74

33m TRT
152.97
5.13
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One Way Analysis of Variance
Data source: Data 1 in Notebook 6
Normality Test:

Passed

Equal Variance Test:
Group Name
6 Cont
3
33m Cont 3
33 m Trt
3

N
0
0
0

(P = 0.390)

Passed

(P = 0.744)

Missing Mean Std Dev
25.800 0.954 0.551
34.733 1.365 0.788
39.467 1.872 1.081

SEM

Source of Variation DF
SS
MS
F
P
Between Groups
2
288.987 144.493 69.062 <0.001
Residual
6
12.553
2.092
Total
8
301.540
The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = <0.001).
Power of performed test with alpha = 0.050: 1.000

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method):
Comparisons for factor:
Comparison
Diff of Means
33 m Trt vs. 6 Cont
13.667
33 m Trt vs. 33m Cont
4.733
33m Cont vs. 6 Cont
8.933

p
q
P
P<0.050
3 16.365 <0.001 Yes
2
5.668 0.007 Yes
2 10.697 <0.001 Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films

%C
%C
%C
N
Mean
Strandard Deviation
Standard Error of the mean

6m CON
24
17.7
11
3
17.57
6.50
4.60

33m CON 33 m TRT
42.8
33.2
47.4
34.9
47.6
41.5
3
3
45.93
36.53
2.72
4.38
1.92
3.10

Relative Expression Level
Standard error of the mean

6m CON
1.00
0.26

33m CON
2.6148
0.11

33m TRT
2.08
0.18

% RE
SE

6m CON
100.00
26.17

33m CON
261.48
10.93

33m TRT
207.97
17.65
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One Way Analysis of Variance
Data source: Data 1 in Notebook 7
Normality Test:

Passed

Equal Variance Test:
Group Name
6m Cont
3
33m Cont 3
33 m Trt
3

N
0
0
0

(P = 0.734)

Passed

(P = 0.422)

Missing Mean Std Dev
17.567 6.501 3.753
45.933 2.715 1.568
36.533 4.384 2.531

SEM

Source of Variation DF
SS
MS
F
P
Between Groups
2
1252.762 626.381 27.289 <0.001
Residual
6
137.720 22.953
Total
8
1390.482
The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = <0.001).
Power of performed test with alpha = 0.050: 0.999

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) :
Comparisons for factor:
Comparison
Diff of Means
33m Cont vs. 6m Cont 28.367
33m Cont vs. 33 m Trt
9.400
33 m Trt vs. 6m Cont
18.967

p
q
P
P<0.050
3 10.255 0.001 Yes
2
3.398 0.053
No
2
6.857 0.003 Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films
Ferritin light chain

6m CON
36
36
34
6m CON
35
33
33
6m CON
1.04
1.10
1.03

33m CON
32
32
35
33m CON
32
34
35
33m CON
1.00
0.96
1.01

33 m TRT
32
32
31
33 m TRT
33
33
32
33 m TRT
0.95
0.95
0.96

N
Mean

3.00
1.06

3.00
0.99

3.00
0.95

STDEV
SEM

0.04
0.03

0.03
0.02

0.01
0.01

6m CON
1.00

33m CON
0.94

33m TRT
0.90

0.02

0.01

panceau stain

Ratio

Relative expression
Standard error of the
mean

% RE
SE

0.03

6m CON
33m CON
100.00
93.64
2.57
1.87

33m TRT
90.11
0.61
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One Way Analysis of Variance
Data source: Data 1 in Notebook 1
Normality Test:

Passed

Equal Variance Test:
Group Name
6m CON
3
33m CON 3
33 m TRT 3

N
0
0
0

Source of Variation DF
Between Groups
2
Residual
6
Total
8

(P = 0.770)

Passed
Missing
1.057
0.990
0.953

(P = 0.496)

Mean Std Dev SEM
0.0384 0.0222
0.0279 0.0161
0.00906 0.00523

SS
MS
F
P
0.0169 0.00843 10.815 0.010
0.00467 0.000779
0.0215

The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.010).
Power of performed test with alpha = 0.050: 0.867

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method):
Comparisons for factor:
Comparison
Diff of Means
6m CON vs. 33 m TRT 0.105
6m CON vs. 33m CON 0.0672
33m CON vs. 33 m TRT0.0374

p
3
2
2

q
P
P<0.050
6.490 0.009 Yes
4.171 0.026 Yes
2.318 0.152
No
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films
Ferritin light chain

6m CON
23.3
20.6
24.5

33m CON
40
35.1
33

33 m TRT
36.7
44.3
42.6

panceau stain

6m CON
34.5
32.8
32.7

33m CON
31
33.7
34.8

33 m TRT
33.2
33.4
32.4

Ratio

6m CON
0.675362
0.628049
0.749235

33m CON
1.2903226
1.041543
0.9482759

33 m TRT
1.1054217
1.3263473
1.3148148

N
Mean

3
0.684216

3
1.0933805

3
1.2488613

STDEV
SEM

0.061076
0.043188

0.1768172
0.1250287

0.1243561
0.087933

6m CON
1

33m CON
1.598006

33 m TRT
1.8252454

0.06

0.18

0.13

Relative expression
Standard error of the
mean

% RE
SE

6m CON 33m CON
33m TRT
100 159.8006
182.52454
6.311988 18.273286
12.851656
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One Way Analysis of Variance
Data source: Data 1 in Notebook 1
Normality Test:

Passed

Equal Variance Test:
Group Name
6m CON
3
33m CON 3
33 m TRT 3

N
0
0
0

Source of Variation DF
Between Groups
2
Residual
6
Total
8

(P = 0.602)

Passed
Missing
0.684
1.093
1.249

(P = 0.615)
Mean Std Dev
0.0611 0.0353
0.177 0.102
0.124 0.0718

SEM

SS
MS
F
P
0.510 0.255 15.173 0.004
0.101 0.0168
0.611

The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.004).
Power of performed test with alpha = 0.050: 0.960

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method):
Comparisons for factor:
Comparison
Diff of Means
33 m TRT vs. 6m CON 0.565
33 m TRT vs. 33m CON0.155
33m CON vs. 6m CON 0.409

p
3
2
2

q
P
P<0.050
7.541 0.004 Yes
2.076 0.193
No
5.464 0.009 Yes

94

95

Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films

DMT1

6m CON
23
21
25

33m CON
40
35
33

33 m TRT
37
44
43

ponceau stain

6m CON
32.8
33.3
33

33m CON
32
34.2
33.9

33 m TRT
35.2
32.5
33

Ratio

6m CON
0.70122
0.630631
0.757576

33m CON
1.25
1.0233918
0.9734513

33 m TRT
1.0511364
1.3538462
1.3030303

N
Mean

3
0.696475

3
1.082281

3
1.2360043

STDEV
SEM

0.063605
0.044976

0.1473796
0.1042131

0.1621039
0.1146248

6m CON

33m CON

33 m TRT

1

1.5539403

1.7746563

0.06

0.15

0.16

Relative expression
Standard error of the
mean

% RE
SE

6m CON
33m CON
33m TRT
100 155.39403 177.46563
6.457632 14.962931 16.457835
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One Way Analysis of Variance
Data source: Data 1 in Notebook 1
Normality Test:

Passed

Equal Variance Test:
Group Name
6m CON
3
33m CON 3
33 m TRT 3

N
0
0
0

Source of Variation DF
Between Groups
2
Residual
6
Total
8

(P = 0.800)

Passed
Missing
0.696
1.082
1.236

(P = 0.715)
Mean Std Dev
0.0636 0.0367
0.147 0.0851
0.162 0.0936

SEM

SS
MS
F
P
0.464 0.232 13.361 0.006
0.104 0.0173
0.568

The differences in the mean values among the treatment groups are greater than would
be expected by chance; there is a statistically significant difference (P = 0.006).
Power of performed test with alpha = 0.050: 0.933

All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method):
Comparisons for factor:
Comparison
Diff of Means
33 m TRT vs. 6m CON 0.540
33 m TRT vs. 33m CON0.154
33m CON vs. 6m CON 0.386

p
3
2
2

q
P
P<0.050
7.095 0.006 Yes
2.022 0.203
No
5.073 0.012 Yes
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films
IRP1

6m CON
29.4
31.1
33.6

33m CON
34
35.3
38.2

33 m TRT
36.6
33.6
28.1

ponceau stain

6m CON
33m CON
33 m TRT
32.8
32
35.2
33.3
34.2
32.5
33
33.9
33

Ratio

6m CON
33m CON
33 m TRT
0.896341
1.0625
1.0397727
0.933934 1.0321637
1.0338462
1.018182 1.1268437
0.8515152

N
Mean
STDEV
SEM

3
0.949486
0.062391
0.044117
6m CON

Relative expression
Standard error of the
mean

% RE
SE

3
1.0738358
0.0483471
0.0341866

3
0.9750447
0.1070207
0.0756751

33m CON
33 m TRT
1 1.1309657
1.0269187

0.046464

0.0360054

0.0797011

6m CON
33m CON
33m TRT
100 113.09657
102.69187
4.646435 3.6005383
7.9701135
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One Way Analysis of Variance
Data source: Data 1 in Notebook 1
Normality Test:

Passed

Equal Variance Test:
Group Name
6m CON
3
33m CON 3
33 m TRT 3

N
0
0
0

Source of Variation DF
Between Groups
2
Residual
6
Total
8

(P = 0.355)

Passed
Missing
0.949
1.074
0.975

(P = 0.828)
Mean Std Dev
0.0624 0.0360
0.0483 0.0279
0.107 0.0618

SEM

SS
MS
F
P
0.0259 0.0129 2.195 0.193
0.0354 0.00589
0.0612

The differences in the mean values among the treatment groups are not great enough
to exclude the possibility that the difference is due to random sampling variability; there
is not a statistically significant difference (P = 0.193).
Power of performed test with alpha = 0.050: 0.173
The power of the performed test (0.173) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one
actually exists. Negative results should be interpreted cautiously.
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Raw data
This section represents the raw data tables produced from spot densitometry of the
immunoblot films

TfR1

6m CON
31.9
33.00
33.9

33m CON
33.8
33.00
31.7

33 m TRT
34.3
34.00
34.4

ponceau stain

6m CON
33m CON
33 m TRT
33.9
33.3
32.7
32.8
33.7
33.4
34
33.7
32.2

Ratio

6m CON
33m CON
33 m TRT
0.941003
1.015015 1.0489297
1.006098 0.9792285 1.0179641
0.997059 0.9406528 1.068323

N
Mean
STDEV
SEM

3
0.981386
0.035264
0.024935
6m CON

Relative expression
Standard error of the
mean

3
3
0.9782988 1.0450722
0.0371898 0.0254001
0.0262972 0.0179606

1

33m CON
33 m TRT
0.9968538 1.0648937

0.025408

0.0267959 0.0183012
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One Way Analysis of Variance
Data source: Data 1 in Notebook 1
Normality Test:

Passed

Equal Variance Test:
Group Name
6m CON
3
33m CON 3
33 m TRT 3

N
0
0
0

Source of Variation DF
Between Groups
2
Residual
6
Total
8

(P = 0.505)

Passed
Missing
0.981
0.978
1.045

(P = 0.839)
Mean Std Dev
0.0353 0.0204
0.0372 0.0215
0.0254 0.0147

SEM

SS
MS
F
P
0.00852 0.00426 3.908 0.082
0.00654 0.00109
0.0151

The differences in the mean values among the treatment groups are not great enough
to exclude the possibility that the difference is due to random sampling variability; there
is not a statistically significant difference (P = 0.082).
Power of performed test with alpha = 0.050: 0.366
The power of the performed test (0.366) is below the desired power of 0.800.
Less than desired power indicates you are less likely to detect a difference when one
actually exists. Negative results should be interpreted cautiously.

